Trials / Recruiting
RecruitingNCT05561205
rTMS for Apathy Clinical Trial
Repetitive Transcranial Magnetic Stimulation for Apathy Clinical Trial (REACT)
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Sunnybrook Health Sciences Centre · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Apathy is a common, early, and disabling symptom in dementias and mild behavioural impairment such as Alzheimer's disease (AD) and is characterized by lack of interest and enthusiasm. Both repetitive transcranial magnetic stimulation (rTMS), a form of non-invasive brain stimulation, and methylphenidate, a medication, have been shown to improve apathy. This pilot study will investigate rTMS as a treatment for apathy in neurocognitive disorders and mild behavioural impairment in individuals receiving methylphenidate and individuals not receiving medication for apathy.
Conditions
- Alzheimer Disease
- Apathy in Dementia
- Dementia
- Mild Behavioural Impairment
- Mild Cognitive Impairment
- Neurocognitive Disorders
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | rTMS | repetitive transcranial magnetic stimulation |
| DRUG | methylphenidate | methylphenidate |
Timeline
- Start date
- 2023-02-09
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2022-09-30
- Last updated
- 2026-04-13
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT05561205. Inclusion in this directory is not an endorsement.